NASDAQ:LGNDLigand Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $108.64 +2.66 (+2.51 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$104.58Now: $108.64▼$108.8850-Day Range$73.23MA: $95.83▼$108.6452-Week Range$57.24Now: $108.64▼$122.08Volume202,500 shsAverage Volume357,925 shsMarket Capitalization$1.74 billionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $163.20, Ligand Pharmaceuticals has a potential upside of 50.2% from its current price of $108.64.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesLigand Pharmaceuticals has received 493 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLigand Pharmaceuticals has received 367 “underperform” votes. (Add your “underperform” vote.)Community SentimentLigand Pharmaceuticals has received 57.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote “Outperform” if you believe LGND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold 459.92% more of their company's stock than they have bought. Specifically, they have bought $141,941.00 in company stock and sold $794,750.00 in company stock.Percentage Held by InsidersOnly 10.20% of the stock of Ligand Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 19.77% in the coming year, from $2.63 to $3.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is -31.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is -31.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND Previous Symbol CUSIP53220K50 CIK886163 Webwww.ligand.com Phone858-550-7500Debt Debt-to-Equity Ratio0.69 Current Ratio40.65 Quick Ratio40.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio41.31 P/E Growth2.75 Sales & Book Value Annual Sales$120.28 million Price / Sales14.50 Cash Flow$5.98 per share Price / Cash Flow18.16 Book Value$41.24 per share Price / Book2.63Profitability EPS (Most Recent Fiscal Year)$2.11 Net Income$629.30 million Net Margins-55.63% Return on Equity3.68% Return on Assets2.03%Miscellaneous Employees116 Outstanding Shares16,050,000Market Cap$1.74 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:LGND Rates by TradingView Receive LGND News and Ratings via Email Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions How has Ligand Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LGND stock has increased by 18.3% and is now trading at $108.64. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ligand Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ligand Pharmaceuticals. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Ligand Pharmaceuticals. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported $0.89 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.66 by $0.23. The biotechnology company earned $33.16 million during the quarter, compared to analysts' expectations of $26.70 million. Ligand Pharmaceuticals had a negative net margin of 55.63% and a positive return on equity of 3.68%. The firm's revenue for the quarter was down 23.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.16 EPS. View Ligand Pharmaceuticals' earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY20 earnings guidance on Wednesday, May, 6th. The company provided EPS guidance of approx $3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.59. The company issued revenue guidance of approx $140 million, compared to the consensus revenue estimate of $131.03 million. What price target have analysts set for LGND? 6 analysts have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $132.00 to $229.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $163.20 in the next year. This suggests a possible upside of 50.2% from the stock's current price. View analysts' price targets for Ligand Pharmaceuticals. Has Ligand Pharmaceuticals been receiving favorable news coverage? News articles about LGND stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutLigand Pharmaceuticals. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Intel (INTC), Gilead Sciences (GILD), Cisco Systems (CSCO) and Illumina (ILMN). Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the following people: Mr. John L. Higgins, CEO & Exec. Director (Age 49)Mr. Matthew W. Foehr, Pres & COO (Age 46)Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Todd Pettingill, Director of Corp. Devel. What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.92%), William Blair Investment Management LLC (9.47%), Wasatch Advisors Inc. (4.30%), Conestoga Capital Advisors LLC (3.93%), Villere ST Denis J & Co. LLC (3.96%) and Rice Hall James & Associates LLC (2.11%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Sunil Patel and Todd C Davis. View institutional ownership trends for Ligand Pharmaceuticals. Which institutional investors are selling Ligand Pharmaceuticals stock? LGND stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Thrivent Financial for Lutherans, The Manufacturers Life Insurance Company , Janus Henderson Group PLC, Two Sigma Investments LP, Two Sigma Advisers LP, Rafferty Asset Management LLC, and AQR Capital Management LLC. View insider buying and selling activity for Ligand Pharmaceuticals. Which institutional investors are buying Ligand Pharmaceuticals stock? LGND stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Villere ST Denis J & Co. LLC, Stonepine Capital Management LLC, William Blair Investment Management LLC, Tygh Capital Management Inc., Weiss Multi Strategy Advisers LLC, Impax Asset Management Group plc, and Granahan Investment Management Inc. MA. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel. View insider buying and selling activity for Ligand Pharmaceuticals. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $108.64. How big of a company is Ligand Pharmaceuticals? Ligand Pharmaceuticals has a market capitalization of $1.74 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe. What is Ligand Pharmaceuticals' official website? The official website for Ligand Pharmaceuticals is www.ligand.com. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
